Objectives: The aim of this study was to establish wild-type MIC distributions of first-line drugs for Mycobacterium tuberculosis, as well as to explore the usefulness of such distributions when setting clinical breakpoints.
Introduction
Antimicrobial susceptibility testing (AST) of Mycobacterium tuberculosis is of high priority as resistance, including multidrug resistance, is a rapidly increasing public health concern globally. 1 Broth-based methods such as BACTEC460 or BACTEC960 MGIT (Becton Dickinson, USA) are widely used both for culture and AST. 2, 3 For AST, these methods, based on the proportion method, show a good agreement for the most important bactericidal drugs such as isoniazid and rifampicin but less so for ethambutol and streptomycin in inter-laboratory comparisons. 4 Proficiency testing results from five rounds during 1994 -98 showed that average sensitivities for detection of drug resistance to isoniazid, rifampicin and ethambutol were 98.7%, 97.2% and 89.3%, respectively. 4 -6 Traditionally, AST of M. tuberculosis is based on critical concentrations whereas for other bacterial pathogens the corresponding definition is the clinical breakpoint. The definition of critical drug concentration is defined as the lowest concentration of a drug that will inhibit 95% of wild-type strains of M. tuberculosis that have never been exposed to these drugs. 2 For some first-and most second-line drugs, contrary to the situation with other bacterial pathogens, no clear correlation has been established between the critical concentrations and clinical outcome, with the exception of isoniazid and stretomycin. 7, 8 Regarding pyrazinamide, there is a poor correlation between the higher concentrations used for AST compared with those given for treatment, which is partially due to the need for acidified liquid medium for AST. 7, 9 The concept of utilizing MIC distributions as one of several tools for establishing clinical breakpoints has been widely adopted for most bacterial species, by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), an organization responsible for the currently ongoing harmonization of breakpoints in Europe. 10 A microorganism is defined as wildtype by the absence of acquired and mutational resistance mechanisms to the drug in question. 10 The wild-type MIC distribution is one of several factors taken into consideration by the EUCAST when setting clinical breakpoints, along with pharmacokinetic (PK), pharmacodynamic (PD) and clinical data. 10 Based on these data, breakpoints are established according to the SIR (S, susceptible; I, intermediate; R, resistant) system. Categorical SIR discrepancies will frequently occur if the clinical breakpoint divides the wild-type population, and this factor should therefore always be taken into consideration in order to avoid poor reproducibility in AST. Further, the wild-type cut-off, also labelled the epidemiological cut-off value (ECOFF) by the EUCAST, can be utilized for determining the prevalence of low-level resistance/non-susceptibility for drug/bacteria combinations in situations where there is a gap between the ECOFF and the clinical S breakpoint. 10 One important example of this is fluoroquinolone resistance in Enterobacteriaceae, where the ECOFF is 0.125 mg/L, whereas the S breakpoint is 0.5 mg/L. Isolates with MICs of 0.25-0.5 mg/L may have low-level resistance mechanisms, and the ECOFF can be used to discover such resistance and assist in identifying potential molecular mechanisms of resistance in these isolates. 10 Regarding M. tuberculosis, there are very few reports describing wild-type distributions as has been pointed out previously. 5 MIC determinations and wildtype data might be of great importance in the search for specific genetic resistance mechanisms that can be used for rapid PCR-based methods, such as the GenoType MTBDR assay (Hain LifeScience GmbH, Nehren, Germany), as well as to optimize the use and dosing of the available drugs in multidrug-resistant cases. 11 -13 In this report, we aim to describe MIC distributions of three first-line drugs for M. tuberculosis, as a basis for setting clinical breakpoints according to the criteria used by the EUCAST for other bacterial pathogens. PK/PD data are reviewed, and possible implications for susceptibility breakpoints in relation to high-dose regimens are discussed.
Materials and methods

Strains and quality control
Altogether, 95 consecutive clinical isolates from the Karolinska University Hospital Mycobacteriology Laboratory were tested; 40 in the first round and 55 in the second round. To ascertain that only unique consecutive strains were used, five strains (one from the first round and four from the second round) were excluded as they were confirmed to be a part of four different clusters identified by the restriction fragment length polymorphism (RFLP) database from the Swedish Institute of Disease Control. Thus, 90 consecutive and unique isolates were subjected to MIC determination. The consecutive isolates represent a heterogeneous selection as at least 78% of patients with tuberculosis in Sweden are foreign-born, predominantly originating from highly endemic areas.
14 The strain M. tuberculosis H37Rv (ATCC 27294) was tested in duplicate in both rounds, and one fully susceptible consecutive strain from the first round was tested in the second round. Moreover, in the second round we tested eight additional poly-or multidrug-resistant nonconsecutive isolates from the Karolinska University Hospital Mycobacteriology Laboratory as well as 16 strains from the WHO proficiency test (PT) panel for first-and second-line drug susceptibility testing. 4 Results from the WHO PT panel were available for seven isolates for the first-line drugs. Five of the PT panel strains, including isolates resistant to isoniazid and ethambutol, were tested in duplicate in the second round. All isolates and strains were coded and their identities were blinded to the investigators until the MIC determinations were completed. The drug susceptibility pattern of all isolates had been determined previously under routine conditions using the recommended critical concentrations with the BACTEC460 system (isoniazid, 0.1 mg/L; rifampicin, 2.0 mg/L; ethambutol, 2.5 mg/L).
Antibiotics and substrates
Isoniazid, rifampicin and ethambutol (Sigma-Aldrich, Stockholm, Sweden) stock solutions were prepared by diluting isoniazid and ethambutol in sterile H 2 O and rifampicin in DMSO (Sigma-Aldrich) to reach a concentration of 30.7 g/L. The stock solutions were kept at 2208C. One to two days before use, Middlebrook 7H10 agar (BD AB, Stockholm, Sweden) enriched with 10% oleic acid/albumin/ dextrose/catalase (BD AB) and 5% glycerol was prepared in 14 cm Petri dishes each containing 60 mL of agar. Serial two-step dilutions of the stock solutions were incorporated in the plates reaching final antibiotic concentrations of 0.002 to 512 mg/L. For isoniazid and ethambutol additional plates were made with final antibiotic concentrations of 0.2 and 5 mg/L, respectively, as these are the critical concentrations recommended for susceptibility testing using the proportion method on 7H10 agar. 3 
MIC determinations
All strains were subcultured on Löwenstein -Jensen medium 3 weeks before the experiments. On day 1 colonies were transferred to plastic tubes containing 3 mL of PBS and approximately five glass pearls. The tubes were shaken for 10 min and, after 20 min, 2 mL aliquots of the supernatants were transferred to glass tubes that were refrigerated overnight. On day 2 the suspensions were adjusted to a turbidity equivalent to that of a 0.5 McFarland standard with additional PBS. Subsequently, 200 mL of each adjusted suspension was transferred to 96-well plates. One well was filled with PBS to serve as a negative control. By using a 96-stick replicator 1 mL of each M. tuberculosis isolate suspension was transferred to the Middlebrook plates with the two-step dilution series of the antibiotics beginning with the lowest antibiotic concentrations. Drug-free control plates were replicated before and after each antibiotic plate series. From the 0.5 McFarland standard suspensions, 1:100 dilutions were also prepared for each strain. Thereafter, five drug-free control plates were replicated in the same way with the 1:100 diluted suspensions. The plates were sealed with parafilm and placed in plastic bags and then incubated at 378C for 3 weeks. The MIC was defined as the first antibiotic concentration where there was less growth compared with the 1:100 diluted controls of the corresponding strain, i.e. the lowest concentration of drug that inhibited .99% of the bacterial population. To classify the strains as susceptible or resistant we used the critical concentrations recommended for 7H10 agar by the WHO:
PK/PD calculations
Area under the curve over MIC (AUC/MIC) and the maximum concentration over MIC (C max /MIC) for the free antibiotic fraction as well as the percentage of time above MIC per 24 h (T .MIC) were calculated for isoniazid, ethambutol and rifampicin. The free fraction was calculated by multiplying the percentage of protein binding with AUC or C max and the free fractions of these variables were then divided by the corresponding MIC value. Regarding T .MIC, the concentration for each antibiotic hour by hour was determined from the free fraction of C max and t 1/2 . T .MIC was then calculated by determining the number of hours that the concentration of the antibiotic was above the given MIC divided by 24 h and multiplied by 100. The PK/PD data used for calculations are presented in Table 1 . Standard and increased dosages as previously suggested were included. 7,11,12,15 -17 All parameters were used in the lower range from published data in order to avoid over-interpretation.
7,17
Results Wild-type distributions clearly separate susceptible from resistant strains regarding rifampicin and isoniazid but not ethambutol As for most other bacterial species, the extension of wild-type distribution was 3 -5 log 2 MIC steps. 10 Regarding isoniazid and rifampicin, the wild-type distribution distinctly separated resistant from susceptible strains (Figure 1a and b) . All wild-type isolates were clearly susceptible to isoniazid and rifampicin when applying the recommended critical concentrations for 7H10 and BACTEC460, respectively (Figure 1a and b) . The MIC wildtype distribution for ethambutol demonstrated poor separation between wild-type isolates and strains classified as resistant using the BACTEC460 reference system. The current critical concentration of 5 mg/L for ethambutol in 7H10 is very close to the upper limit of the wild-type MIC distribution (Figure 1c) .
Correlation of susceptibility results between Middlebrook 7H10 and BACTEC460
In general, the agreement compared with BACTEC460 was excellent for isoniazid [ (Table 2 ). These disagreements coincided with isolates where there was poor agreement between laboratories (57.7% -88%; Table 2 ). All strains with discordant results in 7H10 and BACTEC460 for ethambutol were distributed around the present breakpoint for 7H10 (MIC 4-8 mg/L; Figure 1c ). This problematic relation between the MIC wild-type distribution and the breakpoint for ethambutol was confirmed by the finding that the four isolates with an agreement ,95% (64% -88% among 26 laboratories) had MICs of 4-8 mg/L (Table 2) .
PK/PD calculations in relation to wild-type MIC distributions
No PD targets have been defined for M. tuberculosis, and the results should therefore be interpreted carefully. We included AUC/MIC, C max /MIC and T .MIC in our analysis (Table 3) . Using normal dosing, T. MIC (free concentration) for an MIC of 0.125 mg/L ( proposed ECOFF for isoniazid) was estimated to be 25% and 33% with the normal-and high-dose regimen, respectively. Corresponding AUC/MIC and C max /MIC were approximately 130 and 22 for the standard-dose regimen compared with 400 and 65 for the high-dose therapy. For rifampicin, AUC/MIC and C max /MIC at an MIC of 0.5 mg/L ( proposed ECOFF for rifampicin) were around 50 and 4 for the standard dose and 70 and 5 for the high dose, respectively. Corresponding T. MIC was 25% and 29% for the standard dose and the high dose, respectively. Since standard regimens work well for strains without acquired resistance, 4, 5 our data contribute to the setting of appropriate PK/PD targets for tuberculosis treatment. Regarding ethambutol, PK/PD data clearly show that T .MIC, C max /MIC and AUC/MIC were very low for strains with MICs .4 mg/L, potentially indicating that such strains should be less accessible to treatment using single therapy. However, ethambutol is always used in combination with either rifampicin or isoniazid against drug-susceptible isolates. If the tentative PD targets defined for isoniazid and rifampicin were applied to isolates with MICs above the proposed ECOFF, isolates with isoniazid MICs 0.5 and rifampicin MICs 1 were Table 1 . Baseline PK data used for PK/PD calculations 7, 17 Drug Dose theoretically well within reach for treatment using high-dose regimens (Table 3) .
Quality control
There was no MIC variation within the duplicates of the first experiment for H37Rv. In the second experiment, there was one MIC log 2 dilution step variation for isoniazid, but both MIC determinations for rifampicin and ethambutol showed MICs identical to those in the first round. Overall, inter-and intra-assay variation was very low and not more than one log 2 MIC dilution step for M. tuberculosis H37Rv, one susceptible clinical isolate and the five isolates from the WHO PT panel, including strains resistant to isoniazid and rifampicin (Table 4) .
Discussion
Using a highly reproducible method that allowed us to screen many isolates simultaneously, we have shown that the wildtype MIC distributions of first-line drugs used for the treatment of M. tuberculosis are useful to consider when setting clinical breakpoints, similar to what is observed for other bacterial pathogens (www.eucast.org). By combining these data with the results obtained from PK/PD calculations, we were also able to demonstrate that MIC determinations could be important in optimizing chemotherapy with the most effective drugs. Although we used a limited number of isolates, we found a clear separation in the MIC distribution between wildtype isolates and strains with resistance mechanisms regarding isoniazid and rifampicin. However, the usefulness of wild-type MIC distributions to explain and possibly solve methodological problems is clearly shown for ethambutol as the MIC level separating wild-type and resistant isolates in relation to the present critical concentration is difficult to define, offering a potential explanation for the current problems in reproducibility. The problem with the recommended critical concentrations (5 mg/L for 7H10) was confirmed by the fact that all the strains showing a disagreement between 7H10 and BACTEC460 surrounded the ethambutol breakpoint (MIC 4 -8 mg/L). Furthermore, the strains tested for susceptibility to ethambutol in the network of WHO supranational reference laboratories that showed an agreement of ,95% among the 26 reference laboratories were distributed between MICs of 4 and 8 mg/L. It seems inappropriate that the difference between reporting an isolate as susceptible or resistant (4 or 8 mg/L) in different laboratories for ethambutol in many cases could be due to small methodological variation, which is usually regarded as one log 2 MIC dilution step. One way to solve these problems, as partly suggested previously, 7, 18, 19 is by revising the breakpoints in the case of 7H10 so that resistant strains are defined by MIC 8 mg/L. This is likely to increase reproducibility without jeopardizing the clinical outcome and is partly supported by the PK/PD calculations using ethambutol in the upper range of the standard dose and MIC .4 mg/L, as these parameters produce very low values for T .MIC and AUC/MIC (Table 3) . Although the T .MIC, C max /MIC and AUC/MIC values are also low for MIC ¼4 mg/L, even if we used the upper range of the normal dose (25 mg/kg versus 15 mg/kg), the drug has been found effective in a number of clinical studies, 7 which could be attributed to the possibility of synergistic effects between ethambutol and other anti-tuberculosis drugs. The use of 5.0 mg/L as the breakpoint might define treatable strains as resistant and thereby in some cases deny some patients with MDR-tuberculosis treatment with a potentially active drug. Additionally, the difference between 4 mg/L and 5 mg/L seems very small in relation to the methodological variation and from this perspective it is not surprising that current laboratory practices on ethambutol differ. The CLSI (formerly the NCCLS) 20 recommend testing at one low concentration (5.0 mg/L in 7H10) whereas the American Society for Microbiology's manual recommends testing at 5.0 and 10.0 mg/L, but, in fact, question the value of testing at the lower concentration at all. Taken together, the breakpoint concentration of ethambutol needs to be reconsidered for all available methods with regard to wild-type MIC distributions, PK/PD and clinical data to increase reproducibility and clinical utility. Regarding PK/PD calculations, most evidence supports the use of AUC/MIC, 7, 12, 17 and it should be noted that we used all PK parameters in the lower range and did not take variations in the parameters into account. To make a more accurate determination of PK/PD allowing for variability in PK/PD among patients, Monte Carlo simulations could be used, which contribute to the setting of clinical breakpoints by the EUCAST. 10 Besides their value in the setting of breakpoints, MIC wild-type distributions and MIC determinations are also likely to be important in order to use the most effective drugs, isoniazid and rifampicin, optimally. Testing higher concentrations of isoniazid than the critical breakpoint is probably of value in isoniazid-resistant strains, since some low-level resistant isolates (MICs typically ,1 mg/L), usually showing mutations in inhA, might be accessible to treatment with higher doses of isoniazid. 15, 16, 21 Clinically, high-dose isoniazid regimens (16 -18 mg/kg) have been used as suggested by Moulding 21 without increasing toxicity and this has been demonstrated to increase sputum conversion in MDRtuberculosis patients compared with normal isoniazid doses or placebo. 15 However, the MICs of isoniazid for individual strains were not investigated, unlike in a study in South Africa among children, where 80% of the isoniazid-resistant strains were estimated to be accessible for treatment with a high dose of isoniazid using PK modelling. 16 Regarding rifampicin, lowlevel resistant isolates might also be accessible to treatment, but such isolates are known to be rare and none was found in our study, so routine MIC testing is likely to be of limited value. Because high-dose regimens are used in clinical practice, 11 -12,15 MIC determinations or introduction of a modified SIR system might be useful when reporting strains not belonging to the MIC wild-type distribution that could be accessible for therapy using increased doses of the first-line drugs. A similar strategy has been described by Heifets 18 where existing clinical, pharmacological and wild-type data from BACTEC460 in the National Jewish Hospital have been used to classify strains by their MIC into very susceptible, low-level resistant, moderately resistant and highly resistant. 7, 18 The suggested MIC levels for low-level resistant isolates are similar to the MIC levels that could be suggested for intermediately resistant strains based on our PK/PD calculations and MIC wild-type distributions (isoniazid, 0.25-0.5 mg/L; rifampicin, 1-2 mg/L; and ethambutol, 4 mg/L).
In conclusion, we suggest that the present critical concentrations should be re-evaluated based on wild-type MIC distributions and PK/PD data. Moreover, these parameters could be used to optimize the clinical efficacy and dosing of the first-line drugs. 
Transparency declarations
None to declare.
